Alternative-C-Studie

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisip in Combination with Obinutuzumab in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden.


Indolente Lymphome: Register

Einschlusskriterien:
Marginalzonenlymphome oder follikuläre Lymphome
keine Ein- und Ausschlusskriterien!